Pregnant people have an elevated risk of severe COVID-19-related complications compared to their non-pregnant counterparts, underscoring the need for safe and effective therapies. In this review, we summarize published data on COVID-19 therapeutics in pregnancy and lactation to help inform clinical decision-making about their use in this population. Although no serious safety signals have been raised for many agents, data clearly have serious limitations and there are many important knowledge gaps about the safety and efficacy of key therapeutics used for COVID-19. Moving forward, diligent follow-up and documentation of outcomes in pregnant people treated with these agents will be essential to advance our understanding. Greater regulatory push and incentives are needed to ensure studies to obtain pregnancy data are expedited.
Keywords: COVID-19; Remdesivir; bamlanivimab; baricitinib; casirivimab; corticosteroids; etesevimab; imdevimab, monoclonal antibodies; lactation; severe acute respiratory syndrome-coronavirus-2; tocilizumab.
© The Author(s) 2022.